Finally, when administered intraperitoneally, ART inhibited p38, ERK, STAT5, and CREB activation in tumor tissues and the growth of human CML xenograft tumors in mice without exhibiting any significant adverse effects. This evidence concerns the gene STAT5B and chronic myelogenous leukemia, BCR-ABL1 positive.